RESUMO
BACKGROUND: The use of azathioprine (AZA) in dogs is limited by the potential for hepatotoxicity and myelosuppression. HYPOTHESIS/OBJECTIVES: To determine the prevalence of AZA-associated hepatotoxicity in dogs with dermatological conditions receiving alternate-day AZA. The hypothesis was that dogs receiving AZA every other day (EOD) would have a lower prevalence of hepatotoxicity compared to published data for dogs receiving daily AZA. A secondary aim was to determine the prevalence of AZA-associated myelosuppression over the same time period and population. ANIMALS: Forty-one client-owned dogs with dermatological conditions treated with AZA EOD and glucocorticoids with clinical and haematological follow-up available for a minimum of two months of AZA therapy. METHODS: Retrospective analysis of data from April 1994 to July 2020. Hepatotoxicity was defined as elevation of alanine aminotransferase (ALT) at least twofold above the reference range. RESULTS: Azathioprine-associated hepatotoxicity was observed in two of 41 dogs (4.9%), with onset at 18 and 40 days, respectively. One dog receiving AZA at 1.9 mg/kg EOD had a fourfold increase in ALT. The other dog (AZA dose 2.3 mg/kg EOD) had a 30-fold increase in ALT. Azathioprine was not associated with thrombocytopenia, anaemia or neutropenia in any dogs. Lymphopenia developed in one dog (2.4%) with onset at 105 days. CONCLUSIONS AND CLINICAL RELEVANCE: Alternate-day AZA administration with tapering glucocorticoids was well-tolerated in dogs with dermatological conditions.
